Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the initial dose escalation part (phase 1b) of the company's 1b/2a study with the candidate drug fostroxacitabine bralpamide (fostrox) in hepatocellular carcinoma (HCC), in combination with Lenvima®, was successfully completed. The preliminary results from the dose cohorts are positive with a good safety and tolerability profile and no dose-limiting toxicity has been observed. The recommended